{
    "symbol": "PRVB",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-03 21:19:04",
    "content": "  Before we begin, let me remind you that the various remarks we will make today constitute forward-looking statements these include statements about our future plans and expectations in connection with the agreements we entered into with Sanofi and the potential commercialization of teplizumab, clinical study results, regulatory and other developments and time lines related to our product candidates, including our plans to continue working with the FDA as they review our BLA resubmission and continuing our efforts towards securing a potential FDA approval for and commercialization of teplizumab for an at-risk indication, the potential safety, efficacy and commercial success of teplizumab and our other product candidates, financial projections, including our anticipated use of cash and our cash runway; and our business plans and prospects and projected timing for the same."
}